Fly News Breaks for April 7, 2016
BIIB, GILD, VRTX, MDVN, AMGN
Apr 7, 2016 | 08:15 EDT
Leerink analyst Geoffrey Porges says Q1 results could surprise to the upside for large cap Biotechs. The analyst expects Amgen (AMGN) and Medivation (MDVN) to beat consensus revenue estimates by 8%-9% and to deliver significant earnings upside. Despite the limited data from the market, Porges believes Vertex (VRTX) is positioned for a revenue and earnings surprise after cautious guidance. Gilead (GILD), one of the analyst's top picks, may exceed consensus for revenue by 3% and earnings by 10%, while Biogen (BIIB) may beat revenue estimates by 2% and consensus for earnings by 6%, Porges tells investors in a research note.
News For AMGN;MDVN;VRTX;GILD;BIIB From the Last 2 Days
There are no results for your query AMGN;MDVN;VRTX;GILD;BIIB